InsidersTradesSigma
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
无可用的信号评分。
Explore the complete record of transactions filed by Seymour Albert, Directeur Scientifique. Officer active across 1 company, notably Homology Medicines, Inc.. In total, 4 filings have been recorded. Breakdown: 0 buy · 1 sell. Total volume traded: €5k. History available since 9 January 2023. The latest transaction was disclosed on 9 January 2023 (Cession). Regulator: SEC (Form 4). All data is free.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 条申报中的 4 条
Seymour Albert is the Chief Scientific Officer at Homology Medicines, Inc. In this role, he is responsible for leading the scientific initiatives and research within the company. His expertise contributes to the advancement of innovative technologies and treatments developed by the firm. Seymour plays a key role in the research and development strategy, aiming to improve patient outcomes through cutting-edge therapeutic solutions.